Riskpilot← Back to searchSign inGet full accessNordic Pill Pharma Invest AB
ABActiveOrg 5594609421Åkerivägen 17 AActivities of head offices · NACE 7010Est. 20230 employees
Revenue 2024
SEK 9,7M
-23% vs 2023
EBITDA margin
99.0%
-23% vs 2023
Equity ratio
36.8%
Financial strength
Net profit 2024
SEK 5,8M
-23% vs 2023
| Revenue | SEK 9,7M | -23% |
| EBITDA | SEK 9,6M | -23% |
| Net profit | SEK 5,8M | -23% |
| Total assets | SEK 15,9M | +17% |
| Equity | SEK 5,9M | -22% |
| Employees | 0 | — |
Legal name
Nordic Pill Pharma Invest AB
Org number
5594609421
Legal form
Aktiebolag
NACE code
7010 · Activities of head offices
Founded
6 december 2023
Share capital
SEK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall direkt eller indirekt via dotterföretag med inriktning mot både den nationella och internationella marknaden tillhandahålla varor och tjänster inom hälsa, rådgivning och läkemedelsdistribution samt bedriva konsultativ verksamhet inom vård, läkemedel, utbildning och personalbemanning. Bolaget ska även äga, förvalta och bedriva handel med värdepapper samt därmed förenlig verksamhet.
Address
Åkerivägen 17 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 12 540 | 9 693 |
| Staff expenses | — | — |
| EBITDA | 12 540 | 9 600 |
| Depreciation & amort. | — | −0 |
| EBIT | 12 540 | 9 600 |
| Net financials | — | 15 |
| Profit before tax | 9 440 | 7 316 |
| Tax | −1 945 | −1 521 |
| Net profit | 7 495 | 5 795 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 13 670 | 15 932 |
| Equity | 7 525 | 5 870 |
| Long-term debt | — | 0 |
| Short-term debt | 3 045 | 4 662 |
| Total debt | 3 045 | 4 662 |
EBITDA margin
99.0%
This company
15.8%
Market median
+527% vs market
20232024
Equity ratio
36.8%
This company
38.2%
Market median
+4% vs market
20232024
Return on equity
98.7%
This company
18.4%
Market median
+436% vs market
20232024
Net profit margin
59.8%
This company
8.1%
Market median
+638% vs market
20232024
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20232024
Debt / equity
1.71×
This company
0.62×
Market median
-176% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PL Chief Auditor | Chief Auditor | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nordic Pill Pharma Invest AB (this company)
Homeostasis Health ABBoard members of Nordic Pill Pharma Invest AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Lenny Persson | Chief Auditor | 0 companies |
| Lars Daniel Rahmstrid | Chairman | 0 companies |
| Ali Kouchek | Board of Directors | 0 companies |
| Fabian Chia Amiri | Board of Directors | 0 companies |